|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||107.78 - 109.86|
|52 Week Range||69.52 - 127.68|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||37.17|
|Earnings Date||Aug 30, 2021 - Sep 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.70|
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021.
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore plant to a factory owned by Catalent Inc (NYSE: CTLT), the New York Times reported. The company has been on the lookout for an alternative production site since the U.S. government stopped it from using Emergent’s Baltimore plant after workers accidentally contaminated a batch of Johnson & Johnson’s (NYSE: JNJ) vaccine wi